Metabolomics in Diabetic Kidney Disease

Unraveling the Biochemistry of a Silent Killer

Manjula Darshi, Benjamin Van Espen, Kumar Sharma

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The development of new therapies for chronic diseases, such as diabetic kidney disease (DKD), will continue to be hampered by lack of sufficient biomarkers that will provide insights and will be responsive to treatment interventions. The recent application of metabolomic technologies, such as nuclear magnetic resonance and mass spectroscopy, has allowed large-scale analysis of small molecules to be interrogated in a targeted or untargeted manner. Recent advances from both human and animal studies that have arisen from metabolomic analysis have recognized that mitochondrial function and fatty acid oxidation play key roles in the development and progression of DKD. Although many challenges in the technology for clinical chronic kidney disease (CKD) are yet to be validated, there will very likely be ongoing major contributions of metabolomics to develop new biochemical understanding for diabetic and CKD. The clinical application of metabolomics and accompanying bioinformatic tools will likely be a cornerstone of personalized medicine triumphs for CKD.

Original languageEnglish (US)
Pages (from-to)92-103
Number of pages12
JournalAmerican Journal of Nephrology
Volume44
Issue number2
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Metabolomics
Diabetic Nephropathies
Biochemistry
Chronic Renal Insufficiency
Technology
Precision Medicine
Computational Biology
Mass Spectrometry
Chronic Disease
Magnetic Resonance Spectroscopy
Fatty Acids
Biomarkers
Therapeutics

Keywords

  • Chronic kidney disease
  • Diabetic kidney disease
  • GC-MS
  • Metabolomics
  • Mitochondria

ASJC Scopus subject areas

  • Nephrology

Cite this

Metabolomics in Diabetic Kidney Disease : Unraveling the Biochemistry of a Silent Killer. / Darshi, Manjula; Van Espen, Benjamin; Sharma, Kumar.

In: American Journal of Nephrology, Vol. 44, No. 2, 01.09.2016, p. 92-103.

Research output: Contribution to journalReview article

@article{449671f7e8c64e769be100468d2732a7,
title = "Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer",
abstract = "The development of new therapies for chronic diseases, such as diabetic kidney disease (DKD), will continue to be hampered by lack of sufficient biomarkers that will provide insights and will be responsive to treatment interventions. The recent application of metabolomic technologies, such as nuclear magnetic resonance and mass spectroscopy, has allowed large-scale analysis of small molecules to be interrogated in a targeted or untargeted manner. Recent advances from both human and animal studies that have arisen from metabolomic analysis have recognized that mitochondrial function and fatty acid oxidation play key roles in the development and progression of DKD. Although many challenges in the technology for clinical chronic kidney disease (CKD) are yet to be validated, there will very likely be ongoing major contributions of metabolomics to develop new biochemical understanding for diabetic and CKD. The clinical application of metabolomics and accompanying bioinformatic tools will likely be a cornerstone of personalized medicine triumphs for CKD.",
keywords = "Chronic kidney disease, Diabetic kidney disease, GC-MS, Metabolomics, Mitochondria",
author = "Manjula Darshi and {Van Espen}, Benjamin and Kumar Sharma",
year = "2016",
month = "9",
day = "1",
doi = "10.1159/000447954",
language = "English (US)",
volume = "44",
pages = "92--103",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Metabolomics in Diabetic Kidney Disease

T2 - Unraveling the Biochemistry of a Silent Killer

AU - Darshi, Manjula

AU - Van Espen, Benjamin

AU - Sharma, Kumar

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The development of new therapies for chronic diseases, such as diabetic kidney disease (DKD), will continue to be hampered by lack of sufficient biomarkers that will provide insights and will be responsive to treatment interventions. The recent application of metabolomic technologies, such as nuclear magnetic resonance and mass spectroscopy, has allowed large-scale analysis of small molecules to be interrogated in a targeted or untargeted manner. Recent advances from both human and animal studies that have arisen from metabolomic analysis have recognized that mitochondrial function and fatty acid oxidation play key roles in the development and progression of DKD. Although many challenges in the technology for clinical chronic kidney disease (CKD) are yet to be validated, there will very likely be ongoing major contributions of metabolomics to develop new biochemical understanding for diabetic and CKD. The clinical application of metabolomics and accompanying bioinformatic tools will likely be a cornerstone of personalized medicine triumphs for CKD.

AB - The development of new therapies for chronic diseases, such as diabetic kidney disease (DKD), will continue to be hampered by lack of sufficient biomarkers that will provide insights and will be responsive to treatment interventions. The recent application of metabolomic technologies, such as nuclear magnetic resonance and mass spectroscopy, has allowed large-scale analysis of small molecules to be interrogated in a targeted or untargeted manner. Recent advances from both human and animal studies that have arisen from metabolomic analysis have recognized that mitochondrial function and fatty acid oxidation play key roles in the development and progression of DKD. Although many challenges in the technology for clinical chronic kidney disease (CKD) are yet to be validated, there will very likely be ongoing major contributions of metabolomics to develop new biochemical understanding for diabetic and CKD. The clinical application of metabolomics and accompanying bioinformatic tools will likely be a cornerstone of personalized medicine triumphs for CKD.

KW - Chronic kidney disease

KW - Diabetic kidney disease

KW - GC-MS

KW - Metabolomics

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=84978476547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978476547&partnerID=8YFLogxK

U2 - 10.1159/000447954

DO - 10.1159/000447954

M3 - Review article

VL - 44

SP - 92

EP - 103

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 2

ER -